Regeneron Pharmaceuticals Inc Cash Flow Conversion Efficiency
Regeneron Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) has a cash flow conversion efficiency ratio of 0.018x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($574.50 Million) by net assets ($31.71 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Regeneron Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Regeneron Pharmaceuticals Inc (1991–2025)
Cash flow conversion efficiency of Regeneron Pharmaceuticals Inc from 1991 to 2025. This chart illustrates how Regeneron Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Regeneron Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Regeneron Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Regeneron Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Regeneron Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regeneron Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review REGN cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Canadian National Railway Co
TO:CNR
|
0.103x |
|
BAE SYSTEMS ADR/4 LS-025
F:BSPA
|
N/A |
|
Brookfield Asset Management Ltd.
NYSE:BAM
|
0.046x |
|
Infineon Technologies AG
F:IFX
|
0.024x |
|
Caixabank SA
MC:CABK
|
0.011x |
|
Illinois Tool Works Inc
NYSE:ITW
|
0.249x |
|
Xiaomi Corporation
F:3CP
|
0.031x |
|
Schlumberger NV
NYSE:SLB
|
0.050x |
Annual Cash Flow Conversion Efficiency for Regeneron Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Regeneron Pharmaceuticals Inc from 1991 to 2025. Also see Regeneron Pharmaceuticals Inc balance sheet assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $31.26 Billion | $4.98 Billion | 0.159x | +5.77% |
| 2024-12-31 | $29.35 Billion | $4.42 Billion | 0.151x | -14.86% |
| 2023-12-31 | $25.97 Billion | $4.59 Billion | 0.177x | -20.06% |
| 2022-12-31 | $22.66 Billion | $5.01 Billion | 0.221x | -41.35% |
| 2021-12-31 | $18.77 Billion | $7.08 Billion | 0.377x | +58.88% |
| 2020-12-31 | $11.03 Billion | $2.62 Billion | 0.237x | +8.37% |
| 2019-12-31 | $11.09 Billion | $2.43 Billion | 0.219x | -12.58% |
| 2018-12-31 | $8.76 Billion | $2.20 Billion | 0.251x | +17.82% |
| 2017-12-31 | $6.14 Billion | $1.31 Billion | 0.213x | -36.30% |
| 2016-12-31 | $4.45 Billion | $1.49 Billion | 0.334x | -8.28% |
| 2015-12-31 | $3.65 Billion | $1.33 Billion | 0.364x | +23.03% |
| 2014-12-31 | $2.54 Billion | $752.43 Million | 0.296x | -1.84% |
| 2013-12-31 | $1.95 Billion | $588.60 Million | 0.302x | +603.27% |
| 2012-12-31 | $1.25 Billion | $-74.61 Million | -0.060x | +79.46% |
| 2011-12-31 | $485.73 Million | $-141.68 Million | -0.292x | -259.80% |
| 2010-12-31 | $527.82 Million | $96.34 Million | 0.183x | +200.27% |
| 2009-12-31 | $396.76 Million | $-72.23 Million | -0.182x | +14.41% |
| 2008-12-31 | $418.85 Million | $-89.09 Million | -0.213x | -457.65% |
| 2007-12-31 | $460.27 Million | $27.37 Million | 0.059x | -44.17% |
| 2006-12-31 | $216.62 Million | $23.07 Million | 0.107x | +140.08% |
| 2005-12-31 | $114.00 Million | $-30.30 Million | -0.266x | -186.89% |
| 2004-12-31 | $182.54 Million | $-16.91 Million | -0.093x | -107.89% |
| 2003-12-31 | $137.64 Million | $-6.13 Million | -0.045x | +94.11% |
| 2002-12-31 | $145.98 Million | $-110.52 Million | -0.757x | -251.81% |
| 2001-12-31 | $266.36 Million | $-57.32 Million | -0.215x | -40.43% |
| 2000-12-31 | $182.13 Million | $-27.91 Million | -0.153x | -21.59% |
| 1999-12-31 | $109.50 Million | $-13.80 Million | -0.126x | -62.11% |
| 1998-12-31 | $131.20 Million | $-10.20 Million | -0.078x | -77.03% |
| 1997-12-31 | $138.90 Million | $-6.10 Million | -0.044x | +76.87% |
| 1996-12-31 | $106.90 Million | $-20.30 Million | -0.190x | +29.15% |
| 1995-12-31 | $67.90 Million | $-18.20 Million | -0.268x | +12.27% |
| 1994-12-31 | $67.10 Million | $-20.50 Million | -0.306x | +0.12% |
| 1993-12-31 | $98.40 Million | $-30.10 Million | -0.306x | -55.08% |
| 1992-12-31 | $87.20 Million | $-17.20 Million | -0.197x | -208.05% |
| 1991-12-31 | $106.20 Million | $-6.80 Million | -0.064x | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more